One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung CancerA Randomized Clinical Trial
Leora Horn, MD, MS; Ziping Wang, MD; Gang Wu, MD; et al.
Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 DecadesA Blood or Marrow Transplant Survivor Study Report
Smita Bhatia, MD, MPH; Chen Dai, MS; Wendy Landier, PhD; et al.
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node DissectionA Multicenter Prospective Phase 3 Imaging Trial
Thomas A. Hope, MD; Matthias Eiber, MD; Wesley R. Armstrong; et al.
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer
Rahul Aggarwal, MD; Nicholas R. Rydzewski, MD, MPH; Li Zhang, PhD; et al.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast CancerAn Analysis of Data From the I-SPY2 Randomized Clinical Trial
W. Fraser Symmans, MD; Christina Yau, PhD; Yunn-Yi Chen, MD; et al.
Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene
Fang-Chi Hsu, MS; Nicholas J. Roberts, VetMB, PhD; Erica Childs, PhD; et al.
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationThe Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu, MD, PhD; Teresa Macarulla, MD; Milind M. Javle, MD; et al.
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering MyelomaA Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, MD; Elizabeth Hill, MD; Alexander Dew, DO; et al.
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With CancerA Randomized Clinical Trial
Daneng Li, MD; Can-Lan Sun, PhD; Heeyoung Kim, MPH; et al.
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer
Michael B. Foote, MD; James Robert White, PhD; Justin Jee, MD, PhD; et al.
Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer
Michael Li, MD, MPH; Jordan S. Sack, MD, MPH; Phoenix Bell, MD, MS; et al.
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease
Thomas A. Ollila, MD; Shaolei Lu, MD, PhD; Rebecca Masel, MD; et al.
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment
Noa Eliakim-Raz, MD; Amir Massarweh, MD, PhD, MHA; Amos Stemmer, MD; et al.
Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors
Sarah B. Bateni, MD, MAS; Natalie G. Coburn, MD, MSc; Calvin H. L. Law, MD, MPH; et al.
Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication
Jeromie Ballreich, PhD, MHS; Charles Bennet, MD, PhD, MPP; Thomas J. Moore, AB; et al.
Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies
Janice M. Bonsu, MPH; Onaopepo Kola-Kehinde, BS; Lisa Kim, MD; et al.
Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult CancersReview and Research Recommendations
Jeanne S. Mandelblatt, MD, MPH; Tim A. Ahles, PhD; Marc E. Lippman, MD; et al.
Neoadjuvant Endocrine Therapy in Clinical PracticeA Review
Tal Sella, MD; Anna Weiss, MD; Elizabeth A. Mittendorf, MD, PhD; et al.
Unilateral Leg Swelling in a Young Woman
Jason P. Lambden, MSPH, MD; Denise K. Au, MD; Aarati D. Didwania, MD, MSCI
Inferential Challenges for Real-world Evidence in the Era of Routinely Collected Health DataMany Researchers, Many More Hypotheses, a Single Database
Orestis A. Panagiotou, MD, PhD; Ruth Heller, PhD
The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval
Kerrington Powell, BS; Mark P. Lythgoe, MD; Vinay Prasad, MD, MPH
Information Blocking and OncologyImplications of the 21st Century Cures Act and Open Notes
Najeff Waseem, MD; Sheetal Kircher, MD; Josephine L. Feliciano, MD
Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul?
Lohith Gowda, MD; Stuart Seropian, MD
Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge
Laercio Lopes DaSilva, MD; Pedro Nazareth Aguiar Jr, MD, PhD; Gilberto de Lima Lopes, MD, MBA
Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench
Ibiayi Dagogo-Jack, MD
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy
Joseph R. Osborne, MD, PhD; Neil H. Bander, MD; Scott T. Tagawa, MD, MS
Luminal and Basal Subtypes of Metastatic Prostate Cancer
Rodwell Mabaera, MD, PhD
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population
Xuan Wang, PhD; Dae Hyun Kim, MD, MPH, ScD; Lee-Jen Wei, PhD
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population
Tomonori Mizutani, MD, PhD
Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population—Reply
Peter S. Hall, PhD; David A. Cairns, PhD; Matthew T. Seymour, MD
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?
Makoto Kosaka; Tomonori Mizutani, MD, PhD; Hiroto Ishiki, MD
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?
Kanako Ito, MD; Akihiko Shimomura, MD, PhD
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?—Reply
Claire Falandry, MD, PhD; Gilles Freyer, MD, PhD; Eric Pujade-Lauraine, MD, PhD
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?
Ravi Varadhan, PhD, PhD; Nancy L. Schoenborn, MD, MHS
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?
Wenjie Ma, ScD; Mingyang Song, MD, ScD; Andrew T. Chan, MD, MPH
